Table 5.
Cytokine array
| Sham | PAB | AOB | |
|---|---|---|---|
| 22–26 weeks | 22 weeks | 26 weeks | |
| (n = 4) | (n = 4) | (n = 4) | |
| CINC‐2 | 0.56 ± 0.17 | 0.39 ± 0.08 | 0.42 ± 0.19 |
| CINC‐3 | 0.69 ± 0.19 | 0.61 ± 0.04 | 0.61 ± 0.16 |
| CNTF | 0.34 ± 0.19 | 0.40 ± 0.12 | 0.28 ± 0.18 |
| Fractalkine | 0.12 ± 0.12 | 0.15 ± 0.10 | 0.16 ± 0.14 |
| GM‐CSF | 0.20 ± 0.19 | 0.39 ± 0.14 | 1.06 ± 0.16 * , § |
| IFN‐γ | 0.45 ± 0.06 | 0.31 ± 0.11 | 0.95 ± 0.17 * , § |
| IL‐1α | 0.94 ± 0.08 | 0.76 ± 0.21 | 1.22 ± 0.13 § |
| IL‐1β | 0.19 ± 0.05 | 0.23 ± 0.08 | 0.97 ± 0.19 ** , § |
| IL‐4 | 0.99 ± 0.03 | 0.87 ± 0.24 | 1.02 ± 0.25 |
| IL‐6 | 0.23 ± 0.02 | 0.33 ± 0.19 | 1.01 ± 0.26 * , § |
| IL‐10 | 1.13 ± 0.18 | 0.96 ± 0.28 | 1.20 ± 0.26 |
| Leptin | 0.61 ± 0.13 | 0.41 ± 0.36 | 0.45 ± 0.13 |
| LIX | 0.91 ± 0.15 | 0.76 ± 0.27 | 1.43 ± 0.30 |
| MCP‐1 | 0.67 ± 0.21 | 1.19 ± 0.48 | 1.40 ± 0.09 ** |
| MIP‐3α | 0.18 ± 0.08 | 0.35 ± 0.14 | 0.89 ± 0.22 * |
| NGF‐β | 0.23 ± 0.05 | 0.30 ± 0.27 | 0.43 ± 0.22 |
| TIMP‐1 | 0.86 ± 0.11 | 0.90 ± 0.40 | 1.29 ± 0.38 |
| TNF‐α | 0.31 ± 0.08 | 0.91 ± 0.13 * | 2.01 ± 0.36 *** , § |
| VEGF‐A | 0.77 ± 0.21 | 0.81 ± 0.23 | 1.06 ± 0.32 |
AOB, ascending aortic banding; CINC, cytokine‐induced neutrophil chemoattractant; CNTF, cytokine‐induced neutrophil chemoattractant; GM‐CSF, granulocyte–macrophage colony‐stimulating factor; IFN‐γ, interferon‐γ; IL, interleukin; LIX, lipopolysaccharide‐induced CXC chemokine; MCP‐1, monocyte chemoattractant protein‐1; MIP‐3α, macrophage inflammatory protein‐3α; NGF‐β, nerve growth factor‐β; PAB, pulmonary artery banding; TIMP, tissue inhibitor of metalloproteinase‐1; TNF‐α, tumour necrosis factor‐α; VEGF‐A, vascular endothelial growth factor A.
Relative cytokine expression in the soleus muscle as determined by an antibody array.
*
P < 0.05.
**
P < 0.01.
***
P < 0.001 vs. sham.
§
P < 0.05 vs. PAB animals.